For example, high POLR3G gene expression identifies a subgroup of patients with unfavorable survival outcomes in lung adenocarcinoma, esophageal carcinoma, bladder urothelial carcinoma, kidney renal clear cell carcinoma, uterine corpus endometrial carcinoma, and liver hepatocellular carcinoma (Fig. 4l–n, Supplementary Fig 4q–s; low patient count (n = 80) in esophageal carcinoma cohort). The gene discussed is POLR3G; the disease is uterine corpus endometrial carcinoma.